A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration

Keyphrases

• Sham 100%
• Randomized Controlled Trial 100%
• Vascular Endothelial Growth factor-C (VEGF-C) 100%
• Neovascular Age-related Macular Degeneration (nAMD) 100%
• Best-corrected Visual Acuity 57%
• VEGF-D 42%
• ETDRS 42%
• Standard of Care 28%
• Intravitreal Injection 28%
• Neovascular 28%
• Subretinal Fluid 28%
• Ranibizumab 28%
• Spectral-domain OCT 28%
• Wet Age-related Macular Degeneration 28%
• United States 14%
• Israel 14%
• Europe 14%
• High Dose 14%
• Serious Adverse Events 14%
• Adverse Events 14%
• Combination Therapy 14%
• Angiogenesis 14%
• Vascular Endothelial Growth Factor 14%
• Financial Disclosure 14%
• Fluid-filled 14%
• Mean Standard Deviation 14%
• Dose-ranging 14%
• Vascular Permeability 14%
• Structural Results 14%
• Visual Gain 14%
• Intravitreal 14%
• Treatment-naïve 14%
• Visual Acuity Outcome 14%
• Central Subfield Thickness 14%
• Sham-controlled Trial 14%

Medicine and Dentistry

• Randomized Controlled Trial 100%
• Best Corrected Visual Acuity 100%
• Wet Macular Degeneration 100%
• Vasculotropin C 100%
• Vasculotropin D 75%
• Adverse Event 50%
• Optical Coherence Tomography 50%
• Intravitreal Administration 50%
• Age Related Macular Degeneration 50%
• Ranibizumab 50%
• Low Drug Dose 25%
• Arm 25%
• Combination Therapy 25%
• Drug Megadose 25%
• Angiogenesis 25%
• Visual Acuity 25%
• Blood Vessel Permeability 25%
• Vasculotropin A 25%
• Subretinal Fluid 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Randomized Controlled Trial 100%
• Wet Macular Degeneration 100%
• Vasculotropin C 100%
• Vasculotropin D 75%
• Adverse Event 50%
• Intravitreal Administration 50%
• Age Related Macular Degeneration 50%
• Ranibizumab 50%
• Combination Therapy 25%
• Vasculotropin A 25%
• Subretinal Fluid 25%